AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reiterated by investment analysts at FBR & Co in a report released on Monday, May 22nd. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. FBR & Co’s target price indicates a potential upside of 292.77% from the company’s current price.

Separately, Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 27th.

AVEO Pharmaceuticals (AVEO) traded up 4.8888% on Monday, reaching $0.7638. 1,575,407 shares of the company traded hands. The company has a 50-day moving average price of $0.69 and a 200-day moving average price of $0.68. The company’s market capitalization is $84.29 million. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.09.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). AVEO Pharmaceuticals had a negative net margin of 728.85% and a negative return on equity of 836.92%. The business had revenue of $2.53 million for the quarter. Equities research analysts expect that AVEO Pharmaceuticals will post ($0.44) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “AVEO Pharmaceuticals, Inc. (AVEO) Receives “Outperform” Rating from FBR & Co” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/06/16/aveo-pharmaceuticals-aveo-outperform-rating-reiterated-at-fbr-co-updated-updated.html.

In related news, major shareholder Equity Opportunities Iv Growth acquired 6,000,000 shares of the firm’s stock in a transaction on Tuesday, March 28th. The shares were purchased at an average price of $0.50 per share, with a total value of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the company. Paloma Partners Management Co bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth approximately $184,000. Geode Capital Management LLC raised its stake in shares of AVEO Pharmaceuticals by 3.9% in the first quarter. Geode Capital Management LLC now owns 315,153 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 11,870 shares in the last quarter. UBS Oconnor LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth approximately $291,000. Sabby Management LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter worth approximately $513,000. Finally, Sarissa Capital Management LP bought a new stake in shares of AVEO Pharmaceuticals during the fourth quarter worth approximately $917,000. 50.96% of the stock is currently owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.